Clinicians are essential in helping patients access clinical trials that may introduce novel therapies and improved treatment options. Staying up to date on currently recruiting trials allows clinicians to offer patients access to the latest treatment options and more individualized care. Clinicians can help trials identify suitable candidates and contribute to the advancement of medical standards of care. Maintaining awareness of such opportunities also fosters patient trust in clinicians and the medical community overall.
With October recognized as Liver Disease Awareness Month, we wanted to take some time to spotlight some of the top, currently recruiting clinical trials focusing on hepatocellular carcinoma. The following eight clinical trials are all United States-based and currently recruiting. They are arranged by anticipated primary completion date.
Quick View of Featured Trials
| Study Title | Phase | Estimated Enrollment | Study Start | Estimated Primary Completion |
|---|---|---|---|---|
| Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis | 3 | 471 | March 15, 2023 | February 2026 |
| A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer | 2 & 3 | 12 | July 31, 2023 | July 31, 2026 |
| The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC) | 2 | 19 | February 25, 2025 | October 27, 2026 |
| Radiation Therapy with Protons or Photons in Treating Patients with Liver Cancer | 3 | 186 | January 26, 2018 | June 30, 2027 |
| Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial | 1 & 2 | 92 | February 10, 2026 | August 31, 2027 |
| Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | 3 | 1220 | May 6, 2025 | March 16, 2029 |
| A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | 3 | 660 | January 11, 2024 | September 2030 |
| Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma | 2 | 30 | November 11, 2025 | November 1, 2030 |
Hepatocellular Carcinoma Clinical Trials Currently Recruiting
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis (LIVERATION)
- Sponsor: Can-Fite BioPharma
- Goal: This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.
- Interventions: Namodenoson, placebo
- Primary Outcome Measure: Overall survival (OS)
- Timeframe: From the time of randomization until the date of death from any cause, assessed up to 60 months.
- Study Details
- Source
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
- Sponsor: Inova Health Care Services
- Goal: This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy. In addition to the primary endpoint and multiple secondary efficacy endpoints, we will describe changes in quality of life on treatment over time.
- Intervention: Namenda
- Primary Outcome Measure: Patients progression free survival at six months.
- Timeframe: Six months from the start of treatment.
- Study Details
- Source
The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC) ((HCC))
- Sponsor: Inova Health Care Services
- Goal: The purpose of this research is to see the effect of triplet therapy with atezolizumab, bevacizumab, and memantine in treatment of your hepatocellular carcinoma.
- Interventions: Memantine hydrochloride, bevacizumab, atezolizumab
- Primary Outcome Measure: Objective response rate of patients who are treated with the combination of atezolizumab, bevacizumab, and memantine.
- Timeframe: Up to two years.
- Study Details
- Source
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
- Sponsor: NRG Oncology
- Goal: This phase III trial studies how well radiation therapy with protons works compared with photons in treating patients with liver cancer.
- Interventions: Biospecimen collection, CT, MRI, laboratory biomarker analysis, quality-of-life assessment, radiation therapy
- Primary Outcome Measures: Overall survival; Treatment effect.
- Timeframe: From the date of randomization to the date of death due to any cause assessed up to four years; Up to four years.
- Study Details
- Source
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
- Sponsor: National Cancer Institute (NCI)
- Goal: This phase I/II trial studies the side effects and best dose of sapanisertib when given together with cabozantinib, and to see how well they work in treating patients with liver cancer that has spread from where it first started to other places in the body (metastatic) and contains a mutation (change) in the β-catenin gene.
- Interventions: Biospecimen collection, cabozantinib S-malate, imaging procedure, spanisertib
- Primary Outcome Measures: Dose-limiting toxicities and incidence of adverse events; Progression free survival.
- Timeframe: From registration to disease progression or death due to any cause, assessed up to two years; From registration to disease progression or death due to any cause assessed up to two years.
- Study Details
- Source
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma (ARTEMIDE-HCC01)
- Sponsor: AstraZeneca
- Goal: This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy.
- Interventions: Tremelimumab, rilvegostomig, bevacizumab, atezolizumab
- Primary Outcome Measure: To demonstrate the efficacy of Arm A relative to Arm C by assessment of OS in participants with advanced HCC.
- Timeframe: Up to approximately six years.
- Study Details
- Source
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2)
- Sponsor: AbbVie
- Goal: The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab.
- Interventions: Livmoniplimab, budigalimab, durvalumab, atezolizumab, bevacizumab, tremelimumab
- Primary Outcome Measures: Stage 1: Best overall response (BOR) per investigator; Stage 2: Overall Survival (OS).
- Timeframe: Through study completion, up to approximately 56 months; Through study completion up to approximately 56 months.
- Study Details
- Source
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
- Sponsor: University of Miami
- Goal: The purpose of this study is to determine the effects that Regorafenib in combination with Yttrium-90 (Y-90) radioembolization has on patients with unresectable hepatocellular carcinoma.
- Interventions: Regorafenib, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
- Primary Outcome Measures: Disease control rate measured by number of points; Number of participants experiencing treatment-related adverse events; Number of participants experiencing treatment-related serious adverse events.
- Timeframe: Up to 24 months; Up to 25 months; Up to 25 months.
- Study Details
- Source
Sign up for alerts and stay informed on the latest published clinical guidelines and guideline updates.
Copyright © 2025 Guideline Central, all rights reserved.